相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increased Serine and One-Carbon Pathway Metabolism by PKCλ/l Deficiency Promotes Neuroendocrine Prostate Cancer
Miguel Reina-Campos et al.
CANCER CELL (2019)
ATM deficiency promotes progression of CRPC by enhancing Warburg effect
Lingfan Xu et al.
ENDOCRINE-RELATED CANCER (2019)
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
Yu Yin et al.
MOLECULAR CANCER (2019)
ONECUT2 is a driver of neuroendocrine prostate cancer
Haiyang Guo et al.
NATURE COMMUNICATIONS (2019)
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
Yanjing Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Expanding World of N-MYC-Driven Tumors
David S. Rickman et al.
CANCER DISCOVERY (2018)
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Qiuhui Li et al.
NATURE COMMUNICATIONS (2018)
Regulation of SLC1A4 and SLC1A5 in Prostate Cancer-Response
Mark A. White et al.
MOLECULAR CANCER RESEARCH (2018)
FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate
Jung Wook Park et al.
MODERN PATHOLOGY (2017)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Rodrigo Romero et al.
NATURE MEDICINE (2017)
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
Ping Mu et al.
SCIENCE (2017)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Sheng Yu Ku et al.
SCIENCE (2017)
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal et al.
NATURE COMMUNICATIONS (2017)
The Metabolic Phenotype of Prostate Cancer
Eric Eidelman et al.
FRONTIERS IN ONCOLOGY (2017)
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition
Michael Lampa et al.
PLOS ONE (2017)
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Niki Marie i Zacharias et al.
SCIENTIFIC REPORTS (2017)
Glutamine Metabolism in Cancer: Understanding the Heterogeneity
Ahmad A. Cluntun et al.
TRENDS IN CANCER (2017)
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Etienne Dardenne et al.
CANCER CELL (2016)
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
John K. Lee et al.
CANCER CELL (2016)
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Gao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma
Wei Li et al.
MOLECULAR CANCER RESEARCH (2016)
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation
Min Pan et al.
NATURE CELL BIOLOGY (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
CFIm25 regulates glutaminase alternative terminal exon definition to modulate miR-23 function
Chioniso P. Masamha et al.
RNA (2016)
From Krebs to clinic: glutamine metabolism to cancer therapy
Brian J. Altman et al.
NATURE REVIEWS CANCER (2016)
Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer
Zhong Chen et al.
EMBO JOURNAL (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Androgen-regulated metabolism and biosynthesis in prostate cancer
Stefan J. Barfeld et al.
ENDOCRINE-RELATED CANCER (2014)
Molecular Characterization of Prostate Cancer Following Androgen Deprivation: The Devil in the Details
Christopher E. Barbieri et al.
EUROPEAN UROLOGY (2014)
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Matt I. Gross et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation
Lisha Xiang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
Francisca Vazquez et al.
CANCER CELL (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Christopher T. Hensley et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The role of estrogen and androgen receptors in bone health and disease
Stavros C. Manolagas et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer
Steven Kregel et al.
PLOS ONE (2013)
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Lina Gao et al.
PLOS ONE (2013)
Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism
Alexandre Cassago et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma
Sheng Tai et al.
PROSTATE (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species
Sawako Suzuki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
MYC, microRNAs and glutamine addiction in cancers
Chi V. Dang
CELL CYCLE (2009)
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Ping Gao et al.
NATURE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
David R. Wise et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Mariia Yuneva et al.
JOURNAL OF CELL BIOLOGY (2007)
Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer
JT Huang et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
分享论文
